Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 8
2016 5
2017 7
2018 12
2019 24
2020 34
2021 31
2022 20
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma.
Zhang W, Jiang X, Zou Y, Yuan L, Wang X. Zhang W, et al. Front Pharmacol. 2023 Mar 8;14:1092767. doi: 10.3389/fphar.2023.1092767. eCollection 2023. Front Pharmacol. 2023. PMID: 36969873 Free PMC article.
Base on the above observation, the combination of pexidartinib and PD-1 antibody were used in the treatment of lung adenocarcinoma subcutaneous tumor model, the combination therapy has significantly improved the efficacy of tumor treatment compared with the monother …
Base on the above observation, the combination of pexidartinib and PD-1 antibody were used in the treatment of lung adenocarci …
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J, Yang J, Wang W, Guo D, Zhang C, Wang S, Lu X, Huang X, Wang P, Zhang G, Zhang J, Wang J, Cai Z. Chen J, et al. Cell Mol Immunol. 2022 Nov;19(11):1290-1301. doi: 10.1038/s41423-022-00926-6. Epub 2022 Oct 11. Cell Mol Immunol. 2022. PMID: 36220994 Free PMC article.
PD-L1(+) tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 antibody (alphaPD-L1) blockade. However, whether and how PD-L1(+) TEVs mediate alphaPD-L1 therapy resistance is unknown. ...
PD-L1(+) tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 an
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Tap WD, et al. Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19. Lancet. 2019. PMID: 31229240 Free PMC article. Clinical Trial.
Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group. Individuals in the pexidartinib group re …
Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assig …
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Zhu Y, et al. Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22. Gut. 2019. PMID: 30902885
In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumour tissues from patients with HCC. ...Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged sur …
In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumo …
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Omstead AN, Paskewicz M, Gorbunova A, Zheng P, Salvitti MS, Mansoor R, Reed P, Ballengee S, Wagner PL, Jobe BA, Kelly RJ, Zaidi AH. Omstead AN, et al. Carcinogenesis. 2022 Oct 22;43(9):842-850. doi: 10.1093/carcin/bgac043. Carcinogenesis. 2022. PMID: 35552655
In this study, we investigated the antitumor activity of pexidartinib alone or in combination with blockade of PD-1 in a de novo EAC rat model. Here, we showed limited toxicity with significant tumor shrinkage in pexidartinib treated animals compared to contr …
In this study, we investigated the antitumor activity of pexidartinib alone or in combination with blockade of PD-1 in a de no …
Pexidartinib: First Approval.
Lamb YN. Lamb YN. Drugs. 2019 Nov;79(16):1805-1812. doi: 10.1007/s40265-019-01210-0. Drugs. 2019. PMID: 31602563 Free PMC article. Review.
This approval was based on positive results from the phase III ENLIVEN trial. Pexidartinib is being investigated in various malignancies as monotherapy or combination therapy. This article summarizes the milestones in the development of pexidartinib leading to its f …
This approval was based on positive results from the phase III ENLIVEN trial. Pexidartinib is being investigated in various malignanc …
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, Rajasekhar VK, Yoshida A, Kondo H, Hata T, Tazawa H, Dogan Y, Moore MAS, Fujiwara T, Ozaki T, Purdue E, Healey JH. Fujiwara T, et al. Mol Cancer Ther. 2021 Aug;20(8):1388-1399. doi: 10.1158/1535-7163.MCT-20-0591. Epub 2021 Jun 4. Mol Cancer Ther. 2021. PMID: 34088832 Free PMC article.
Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma microenvironment, such as TAMs, is a viable strategy. Here, we investigated the effect of PLX3397 (pexidartinib) as a potent inhibitor …
Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma m …
Engineering an inhibitor-resistant human CSF1R variant for microglia replacement.
Chadarevian JP, Lombroso SI, Peet GC, Hasselmann J, Tu C, Marzan DE, Capocchi J, Purnell FS, Nemec KM, Lahian A, Escobar A, England W, Chaluvadi S, O'Brien CA, Yaqoob F, Aisenberg WH, Porras-Paniagua M, Bennett ML, Davtyan H, Spitale RC, Blurton-Jones M, Bennett FC. Chadarevian JP, et al. J Exp Med. 2023 Mar 6;220(3):e20220857. doi: 10.1084/jem.20220857. Epub 2022 Dec 30. J Exp Med. 2023. PMID: 36584406 Free PMC article.
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J, Wang S, Guo R, Liu D. Wen J, et al. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114884. doi: 10.1016/j.ejmech.2022.114884. Epub 2022 Oct 29. Eur J Med Chem. 2023. PMID: 36335744 Review.
Pharmacological inhibition of CSF1R has emerged as a promising antitumor strategy, with PLX3397 (pexidartinib) been approved by the FDA for the treatment of tenosynovial giant cell tumor in 2019. ...
Pharmacological inhibition of CSF1R has emerged as a promising antitumor strategy, with PLX3397 (pexidartinib) been approved by the F …
141 results